TCI B6660 is Brivaracetam (CAS 357336-20-0), a pyrrolidinone derivative known in research as a synaptic vesicle protein 2A (SV2A) ligand, supplied strictly as a pharmaceutical research reagent for experimental use. It supports in vitro neuropharmacology studies, structure–activity comparisons, and cell-based screening as a reference compound. Analytical laboratories also use material of documented identity when developing and validating HPLC or LC-MS methods. AMI Scientific provides this TCI reagent in a 25 mg pack size suited to micro-scale assay and standard solution preparation.
—
| Brand | — |
|---|---|
| CAS number | — |
| Molecular formula | — |
| Purity | — |
| Category | — |
| Pack sizes | — |
| Physical form | — |
| Storage | — |
—
- Brázdil (2019). Brivaracetam (Briviact®). Neurologie pro praxi doi:10.36290/neu.2019.093
- (2024). Novel Ru-Catalyzed Asymmetric Hydrogenation Enables 100 Kilogram-Scale Synthesis of Brivaracetam. Synfacts doi:10.1055/s-0043-1773610
- (2019). Brivaracetam/cannabidiol. Reactions Weekly doi:10.1007/s40278-019-65496-x
References were compiled automatically from Crossref and every DOI was verified to exist. AMI Scientific is not affiliated with the authors or the publishers.

